The usage of bevacizumab for malignant pleural effusion (MPE) or malignant pericardial effusion (MPCE) has attracted increasing interest from researchers, but the precise ways of bevacizumab administration remain unknown. Patients with histologically or cytologically confirmed non-small-cell lung cancer (NSCLC) with MPE or MPCE were enrolled in the study and treated with a low dose of single bevacizumab (100 mg) intrapleurally or intrapericardially injected after the drainage of the effusions. The Lung Cancer Symptom Scale (LCSS), efficacy, and safety of drug administration were used as evaluation parameters in this study. The results indicated that lung cancer-related symptoms were significantly improved following treatment, compared with symptoms before the treatment (LCSS, score 494 ± 78 vs. score 377 ± 77, mean ± SD) (). Malignant effusions were well controlled, and the median time to progression (TTP) was 91 days and 111 days in MPE and MPCE, respectively. In addition, no severe side effects were observed, except in one patient with mild dizziness. In summary, the low dose of single bevacizumab (100 mg) with intrapleural or intrapericardial injection is effective and safe in the treatment of lung cancer-mediated malignant effusion, rapidly improving the malignant effusion-related symptoms and quality of life in patients with NSCLC.

中文翻译：

---

单次胸腔内或心包内注射贝伐珠单抗治疗肺癌介导的恶性积液的疗效

贝伐单抗用于治疗恶性胸腔积液 (MPE) 或恶性心包积液 (MPCE) 引起了越来越多研究人员的兴趣，但贝伐单抗给药的确切方式仍然未知。经组织学或细胞学证实患有 MPE 或 MPCE 的非小细胞肺癌 (NSCLC) 患者被纳入该研究，并在积液引流后通过胸腔内或心包内注射低剂量的单一贝伐珠单抗 (100 mg) 进行治疗。本研究使用肺癌症状量表 (LCSS)、疗效和给药安全性作为评估参数。结果表明，与治疗前的症状相比，治疗后肺癌相关症状明显改善（LCSS，评分 494 ± 78 vs. 评分 377 ± 77，平均值 ± SD）（). 恶性积液得到很好的控制，MPE 和 MPCE 的中位进展时间 (TTP) 分别为 91 天和 111 天。此外，除了一名轻度头晕的患者外，没有观察到严重的副作用。综上所述，小剂量单药贝伐珠单抗（100 mg）胸腔内或心包腔内注射治疗肺癌恶性胸腔积液安全有效，可迅速改善NSCLC患者恶性胸腔积液相关症状和生活质量。